CN100519554C - 用於治疗爱滋病之ccr5拮抗剂 - Google Patents

用於治疗爱滋病之ccr5拮抗剂 Download PDF

Info

Publication number
CN100519554C
CN100519554C CNB028076540A CN02807654A CN100519554C CN 100519554 C CN100519554 C CN 100519554C CN B028076540 A CNB028076540 A CN B028076540A CN 02807654 A CN02807654 A CN 02807654A CN 100519554 C CN100519554 C CN 100519554C
Authority
CN
China
Prior art keywords
sub
alkyl
hiv
compound
thienyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028076540A
Other languages
English (en)
Chinese (zh)
Other versions
CN1547580A (zh
Inventor
M·W·米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1547580A publication Critical patent/CN1547580A/zh
Application granted granted Critical
Publication of CN100519554C publication Critical patent/CN100519554C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CNB028076540A 2001-03-29 2002-03-27 用於治疗爱滋病之ccr5拮抗剂 Expired - Fee Related CN100519554C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27993801P 2001-03-29 2001-03-29
US60/279,938 2001-03-29

Publications (2)

Publication Number Publication Date
CN1547580A CN1547580A (zh) 2004-11-17
CN100519554C true CN100519554C (zh) 2009-07-29

Family

ID=23070981

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028076540A Expired - Fee Related CN100519554C (zh) 2001-03-29 2002-03-27 用於治疗爱滋病之ccr5拮抗剂

Country Status (29)

Country Link
US (5) US6720325B2 (enExample)
EP (2) EP1591444B1 (enExample)
JP (2) JP4248251B2 (enExample)
KR (1) KR100613528B1 (enExample)
CN (1) CN100519554C (enExample)
AR (1) AR033452A1 (enExample)
AT (2) ATE466009T1 (enExample)
AU (1) AU2002255947B8 (enExample)
BR (1) BR0208398A (enExample)
CA (1) CA2442227C (enExample)
CZ (1) CZ20032636A3 (enExample)
DE (2) DE60204951T2 (enExample)
DK (1) DK1373256T3 (enExample)
ES (2) ES2342942T3 (enExample)
HU (1) HUP0400349A3 (enExample)
IL (1) IL157551A0 (enExample)
MX (1) MXPA03008853A (enExample)
MY (1) MY128609A (enExample)
NO (1) NO326349B1 (enExample)
NZ (1) NZ527768A (enExample)
PE (1) PE20020996A1 (enExample)
PL (1) PL364560A1 (enExample)
PT (1) PT1373256E (enExample)
RU (1) RU2316553C2 (enExample)
SI (1) SI1373256T1 (enExample)
SK (1) SK287521B6 (enExample)
TW (1) TWI237638B (enExample)
WO (1) WO2002079194A1 (enExample)
ZA (1) ZA200307474B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE466009T1 (de) * 2001-03-29 2010-05-15 Schering Corp Ccr5 antagonisten verwendbar für die behandlung von aids
DE60209736T2 (de) 2001-07-02 2006-11-02 Astrazeneca Ab Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
US7132539B2 (en) * 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
WO2004055011A1 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
AU2004285051A1 (en) * 2003-11-03 2005-05-12 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
EP1725235B1 (en) * 2004-02-05 2009-04-15 Schering Corporation Piperidine derivatives useful as ccr3 antagonists
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
ES2431524T3 (es) * 2004-04-13 2013-11-26 Incyte Corporation Derivados de piperazinilpiperidina como antagonistas de los receptores de quimiocinas
AU2005283326B2 (en) * 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
CN101133048A (zh) * 2005-01-06 2008-02-27 先灵公司 哌嗪化合物的药用盐制备
WO2006074270A2 (en) * 2005-01-06 2006-07-13 Schering Corporation Synthesis of ccr5 receptor antagonists
MX2007010257A (es) 2005-02-23 2007-09-11 Schering Corp Derivados de piperidinil piperidina utiles como inhibidores de receptores de quimiocinas.
KR20070107085A (ko) * 2005-02-23 2007-11-06 쉐링 코포레이션 케모카인 수용체의 억제제로서 유용한 피페리디닐 피페라진유도체
CA2615650A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
US7462485B2 (en) * 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
TW200745087A (en) * 2006-02-24 2007-12-16 Schering Corp CCR5 antagonists useful for treating HIV
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
EP2125733A1 (en) * 2006-12-22 2009-12-02 Schering Corporation Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
JP2011513317A (ja) * 2008-02-29 2011-04-28 シェーリング コーポレイション Ｈｉｖ感染を防止するための予防薬としてのｃｃｒ５アンタゴニストおよびｈｉｖの伝播を抑制する方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066559A1 (en) * 1999-05-04 2000-11-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
AU6135294A (en) 1993-02-12 1994-08-29 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
DE69623485T2 (de) 1995-06-07 2003-01-09 Kimberly-Clark Worldwide, Inc. Inhibierung von exoprotein in absorbierenden produkten
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
EP1003514A4 (en) 1997-07-25 2000-10-11 Merck & Co Inc CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
SK286641B6 (sk) 1999-05-04 2009-03-05 Schering Corporation Piperazínové deriváty užitočné ako CCR5 antagonisty, farmaceutické prípravky s ich obsahom a ich použitie
ATE466009T1 (de) * 2001-03-29 2010-05-15 Schering Corp Ccr5 antagonisten verwendbar für die behandlung von aids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066559A1 (en) * 1999-05-04 2000-11-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists

Also Published As

Publication number Publication date
CN1547580A (zh) 2004-11-17
MXPA03008853A (es) 2003-12-04
JP2004525157A (ja) 2004-08-19
DK1373256T3 (da) 2005-10-10
US7008946B2 (en) 2006-03-07
SK11962003A3 (sk) 2004-03-02
US20040157854A1 (en) 2004-08-12
US7098213B2 (en) 2006-08-29
WO2002079194A1 (en) 2002-10-10
HK1083505A1 (en) 2006-07-07
SI1373256T1 (sl) 2005-12-31
ATE466009T1 (de) 2010-05-15
ES2242856T3 (es) 2005-11-16
HUP0400349A2 (hu) 2004-12-28
DE60204951T2 (de) 2006-05-11
AU2002255947B2 (en) 2005-10-27
KR20030083014A (ko) 2003-10-23
ATE299139T1 (de) 2005-07-15
US6720325B2 (en) 2004-04-13
US6900211B2 (en) 2005-05-31
JP4248251B2 (ja) 2009-04-02
DE60204951D1 (de) 2005-08-11
TWI237638B (en) 2005-08-11
EP1373256A1 (en) 2004-01-02
PL364560A1 (en) 2004-12-13
PT1373256E (pt) 2005-11-30
HUP0400349A3 (en) 2010-03-29
JP2008074862A (ja) 2008-04-03
AR033452A1 (es) 2003-12-17
BR0208398A (pt) 2004-06-15
EP1591444A1 (en) 2005-11-02
MY128609A (en) 2007-02-28
HK1057363A1 (en) 2004-04-02
RU2316553C2 (ru) 2008-02-10
NO326349B1 (no) 2008-11-17
EP1373256B1 (en) 2005-07-06
PE20020996A1 (es) 2002-11-01
DE60236218D1 (de) 2010-06-10
ES2342942T3 (es) 2010-07-19
SK287521B6 (sk) 2010-12-07
RU2003131879A (ru) 2005-05-10
NO20034311D0 (no) 2003-09-26
US20060063771A1 (en) 2006-03-23
CA2442227A1 (en) 2002-10-10
ZA200307474B (en) 2004-12-24
NO20034311L (no) 2003-11-26
IL157551A0 (en) 2004-03-28
US7060701B2 (en) 2006-06-13
AU2002255947B8 (en) 2005-11-17
EP1591444B1 (en) 2010-04-28
US20050143390A1 (en) 2005-06-30
KR100613528B1 (ko) 2006-08-16
CZ20032636A3 (cs) 2003-12-17
CA2442227C (en) 2008-10-28
US20030008877A1 (en) 2003-01-09
US20050059666A1 (en) 2005-03-17
NZ527768A (en) 2005-03-24

Similar Documents

Publication Publication Date Title
EP1373256B1 (en) Ccr5 antagonists useful for treating aids
EP1175401B1 (en) Piperazine derivatives useful as ccr5 antagonists
US8114879B2 (en) Piperazine derivatives useful as CCR5 antagonists
JP4223950B2 (ja) Ｃｃｒ５アンタゴニストとして有用なピペリジン誘導体
AU2002255947A1 (en) CCR5 antagonists useful for treating AIDS
EP1373206B1 (en) Aryl oxime-piperazines useful as ccr5 antagonists
JP2006515851A (ja) Ｃｃｒ５アンタゴニストとして有用なピペリジン誘導体
HK1057363B (en) Ccr5 antagonists useful for treating aids
HK1083505B (en) Ccr5 antagonists useful for treating aids
CN100490811C (zh) 用作ccr5拮抗剂的哌嗪衍生物
HK1088001A (en) Piperazine derivatives useful as ccr5 antagonists
HK1057211B (en) Aryl oxime-piperazines useful as ccr5 antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090729

Termination date: 20120327